Navigation Links
Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Date:6/24/2009

-6 season.

In addition to antibody response, the study also examined cell-mediated immunity. T cell responses in mice vaccinated with the seasonal VLP vaccine were compared with T cell responses in mice vaccinated with a commercial influenza vaccine. Of note, mice vaccinated with the VLP vaccine had higher levels of HA flu-specific CD8+ T cells than mice vaccinated with the commercial vaccine. CD8+ T cells play a role in clearing virus from the respiratory tract, which may be an important factor in preventing influenza-associated pneumonia, a leading cause of flu-related hospitalizations in adults older than 65 years of age.

"This study demonstrates the breadth of the immune response induced by the VLP vaccine," said Ted Ross, Ph.D., Assistant Professor, Center for Vaccine Research, University of Pittsburgh. "Not only did the vaccine induce robust HAI responses, it also induced HA-specific CD8+ T cell responses that were superior to those of a split vaccine. This finding may be reflective of the integrity of the structure of the HA protein presented in the VLP."

"We are pleased with the results of this study, which supported the human clinical trials of our seasonal influenza VLP vaccine," said Dr. Rahul Singhvi, president and CEO of Novavax. "We also observed robust HAI responses among subjects in the clinical trial of our seasonal flu vaccine, which we announced last December, including responses against drifted strains. We look forward to future studies to evaluate the breadth of the immune response induced by our VLP-based influenza vaccines."

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company creating novel vaccines, including H1N1, to address a broad range of infectious diseases worldwide using advanced proprietary virus-like-par
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 RXi Pharmaceuticals ... on discovering and developing innovative therapeutics, primarily in the ... of a public offering of 26 million units at ... for gross proceeds of approximately $10.4 million. Each unit ... a 13-month overallotment purchase right to purchase 0.50 of ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... Douglas J. Swirsky , will present a company ... 11 a.m. EDT on Thursday, June 4, 2015. ... Swirsky,s presentation will be available at the following link:  ... on GenVec,s website.  To access, visit www.genvec.com , ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The Fertility ... our own Dr. Danielle Vitiello has taken on a ... role, Dr. Vitiello will provide guidance, leadership, oversight and ... to count Dr. Vitiello among our team of experienced ... and CEO, Joseph A. Hill, M.D. “Her expertise and ...
(Date:5/28/2015)... May 28, 2015 Whitehouse Laboratories is ... its long term partnership with PTI Inspection Systems. Whitehouse ... provide clients with custom-tailored method development and validation ... currently available. The agreement includes a more formal program ... across organizational lines. This enables a more effective team ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... The ability of brain cells to take in substances ... key ingredient in Alzheimer,s brain plaques, neuroscientists at Washington University ... researchers used a drug to shut down the intake process, ... The change led to a 70 percent drop in levels ...
... D.C. Evidence is growing from animal and human studies ... development of breast cancer - but only if consumed during ... British Journal of Cancer published online today. The challenge ... soy appears to provide a shield against the most common ...
... to be no obstacle when it comes to starting a ... Alchemist Empire, Inc., who invented a trading card game, Elementeo, ... unusual way. At the 235th National Meeting of the ... inventive card game. While other 14-year olds play on their ...
Cached Biology News:Researchers close in on origins of main ingredient of Alzheimer's plaques 2Researchers close in on origins of main ingredient of Alzheimer's plaques 3Evidence now suggests eating soy foods in puberty protects against breast cancer 2Evidence now suggests eating soy foods in puberty protects against breast cancer 314-year-old CEO makes chemistry a game with 'Elementeo' 2
...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Recombinant Mouse sTNF RII/TNFRSF1B...
Biology Products: